Targeting the subtypes of breast cancer: rethinking investigational drugs.

The choice of adjuvant treatments for women with breast cancer is based on several features that take into account the heterogeneity of the disease. Questions raised during the decision process include the following: i) What leads to the use of endocrine therapy? ii) What leads to the use of anti-HER2 therapy? iii) What justifies the use of chemotherapy? Choices of adjuvant treatment are based on parameters defined by molecular characterization of breast cancer subtypes or by approximations to this classification using traditional clinical-pathological features. Clinicians should consider cases within the various distinct subpopulation in order to properly select the most 'personalized' adjuvant therapeutic approach. Sensitivity to chemotherapy and/or targeted agents in subtypes of breast cancers are predictable based on gene pathway alterations and associated gene products. This review covers several clinical data on several investigational agents for early-stage breast cancer molecular subtypes. We selected from literature data prospective Phase I, II and III clinical trials of chemotherapy (weekly or daily schedules), including indicators of activity and toxicity and data on survival/mortality. The future of many investigational therapeutics in breast cancer is linked to our ability to identify the most druggable target in each subtype.

Citation

Giuseppe Curigliano, Marzia Locatelli, Luca Fumagalli, Janaina Brollo, Elisabetta Munzone, Franco Nolé, Carmen Criscitiello, Aron Goldhirsch. Targeting the subtypes of breast cancer: rethinking investigational drugs. Expert opinion on investigational drugs. 2012 Feb;21(2):191-204

Mesh Tags

Substances

PMID: 22229343

search → result